investor.minktherapeutics.com Open in urlscan Pro
2a02:26f0:4700::17d4:6ed2  Public Scan

Form analysis
1 forms found in the DOM

GET /

<form class="views-exposed-form" data-drupal-selector="views-exposed-form-widget-sec-filings-table" action="/" method="get" id="views-exposed-form-widget-sec-filings-table" accept-charset="UTF-8">
  <div class="form--inline clearfix">
    <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions"><input data-drupal-selector="edit-reset" type="submit" id="edit-reset" name="op" value="Reset"
        class="button js-form-submit form-submit visually-hidden">
    </div>
  </div>
</form>

Text Content

Skip to main navigation
 * About
   * Overview
   * Management
   * Board of Directors
   * Scientific Advisory Board
 * Our Science
   * iNKT Cells
   * ARDS & Infectious Diseases
   * Cancer
   * GvHD
   * Publications
 * Platform
   * Manufacturing
   * Engineering
 * Pipeline
 * Investor & Media
   * Overview
   * Press Releases
   * Events and Presentations
   * Stock Information
   * Financials & Filings
   * Corporate Governance
 * Careers
 * Contact

Investors
 * Overview
 * Press Releases
 * Events & Presentations
 * Stock
   Stock Quote & Chart Historic Price Lookup
 * Financials
   SEC Filings
 * Governance
   Governance Documents Committee Composition
 * Investor Resources


INVESTOR RELATIONS


COMPANY INFORMATION

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to
developing novel, first-in-class invariant natural killer T (iNKT) cell
therapies to transform the lives of patients with cancer.
Press Releases
Nov 17, 2022
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
NEW YORK , Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ,  a
clinical-stage biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant natural killer T
(iNKT) cell therapies to treat cancer and other immune-mediated
Nov 10, 2022
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination
with pembro/nivo reports early clinical activity in solid tumors, with 27% and
66% of patients, respectively, had a reduction of target and non-target lesions
or disease stabilization First immune cell therapy
Nov 03, 2022
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial
Results
-  Five presentations on clinical data and novel pipeline candidates at the
Society of Cancer Immunotherapy (SITC) Meeting -  R&D Day on November 10, 2022 ,
from 4:00-6:00pm ET in Boston and via webcast NEW YORK , Nov. 03, 2022 (GLOBE
NEWSWIRE) -- MiNK Therapeutics, Inc ., a clinical-stage


 * View All Press Releases

Corporate Presentation
MiNK Therapeutics Corporate Presentation 3.2 MB




SEC FILINGS

Form Description Filing date View 4

Statement of changes in beneficial ownership of securities

Dec 05, 2022 View HTML
0000899243-22-037646.pdf
0000899243-22-037646.rtf
0000899243-22-037646.xls
4

Statement of changes in beneficial ownership of securities

Dec 05, 2022 View HTML
0000899243-22-037650.pdf
0000899243-22-037650.rtf
0000899243-22-037650.xls
4

Statement of changes in beneficial ownership of securities

Dec 05, 2022 View HTML
0000899243-22-037655.pdf
0000899243-22-037655.rtf
0000899243-22-037655.xls
4

Statement of changes in beneficial ownership of securities

Dec 05, 2022 View HTML
0000899243-22-037653.pdf
0000899243-22-037653.rtf
0000899243-22-037653.xls

Data provided by Kaleidoscope.

 * View All SEC Filings

Events and Presentations
5th Annual Evercore ISI HealthCONx Conference
December 1, 2022 at 4:45 PM EST
MiNK Therapeutics Research & Development Day
November 10, 2022 at 4:00 PM EST
MiNK Therapeutics Third Quarter 2022 Financial Results
November 3, 2022 at 8:30 AM EDT


 * View All Events & Presentations





MiNK Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010

Phone: 212.994.8250

Email: webmaster@minktherapeutics.com



Terms and Conditions Privacy Policy Cookie Policy © Copyright 2022. All Rights
Reserved.